Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo

Title:Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo

Volume: 21 Issue: 20

Author(s): Chao Niu , Hunjun Xie and Haji Akber Aisa *

Affiliation:

• State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization and Key Laboratory of Plant Resources and Chemistry of Arid Zone, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi 830011, China
• University of Chinese Academy of Sciences, Beijing, 100049, China

Keywords: JAK-STAT, JAK inhibitors, dermatologic conditions, vitiligo, tofacitinib, ruxolitinib.

Abstract: Abstract: The small-molecular inhibitors targeted JAks (JAK inhibitors) could modulate the cytokines- mediated signaling via the JAK-STAT pathway, which plays an important role in immune regulation and cell proliferation. The JAK inhibitors were previously designed and synthesized to treat diseases involving the hematologic and immune system. Increasing evidence shows that they are quite effective in Atopic Dermatitis (AD), Alopecia Areata (AA), psoriasis, vitiligo, and other autoimmuneinduced dermatologic conditions. Currently, many JAK inhibitors possessing anti-vitiligo activity are being investigated in the laboratory and clinically. In this view, we would like to summarize the applications of these inhibitors with emphasis on the profile of vitiligo, clinical efficacy, dosages, development of new candidates and adverse events through available literature.

Cite this article as:

Niu Chao , Xie Hunjun and Aisa Akber Haji *, Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo, Mini-Reviews in Medicinal Chemistry 2021; 21 (20) . https://dx.doi.org/10.2174/1389557521666210325120233